PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?
Visit https://www.peervoice.com/JCT860 to view the entire programme with slides. After completing “Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?”, participants will be able to: Summarise the current treatment guidelines and the importance of combined positive score (CPS) when evaluating first-line systemic treatment options for patients with recurrent/metastatic squamous cell carcinoma of head and neck (SCCHN); Discuss clinical data that help inform treatment plans in patients with recurrent/metastatic SCCHN; and In patients with CPS between 1 and 19, identify patient and disease characteristics that would differentiate patient suitability for a non-immune checkpoint inhibitor (ICI)-based therapeutic regimen versus an ICI-based regimen.